Advertisement

Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract

  • S. Mani
  • P. J. Johnson
Chapter
  • 113 Downloads

Abstract

Hepatocellular carcinoma (HCC or hepatoma) is one of the most common malignancies. Worldwide, the annual incidence is nearly 1 million and it causes an estimated 1,250,000 deaths every year. There is striking geographic variation, the highest rates being found in China, Southeast Asia, and sub-Saharan Africa (>20, and up to 100/100,000 males per year). The lowest rates (<5/100,000 males per year) are found in Northern Europe, North America, and Latin America [1].

Keywords

Pancreatic Cancer Clin Oncol Carcinoid Tumor Radiat Oncol Biol Phys Gallbladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics, 1996. CA 46:5–27PubMedGoogle Scholar
  2. 2.
    Bosch FX, Munoz N (1991) Hepatocellular carcinoma in the world: epidemiological questions. In: Tabor E, DiBisceglie AM, Purcell RH (eds) Etiology, pathology, and treatment of hepatocellular carcinoma. Portfolio, The Woodlands, Texas, pp 1–10Google Scholar
  3. 3.
    Beasley RP (1988) Hepatitis B virus the major etiology of Hepatocellular carcinoma in theGoogle Scholar
  4. 4.
    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children; Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859PubMedCrossRefGoogle Scholar
  5. 5.
    Ross RK, Yuan JM, Yu MC et al (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339: 943–946PubMedCrossRefGoogle Scholar
  6. 6.
    Brechot C (1998) Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 29:173–183PubMedCrossRefGoogle Scholar
  7. 7.
    Ohtsuki T, Okuda K, Tomimatsu M et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56:918–928PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson PJ (2001) Hepatocellular carcinoma. In: Prognostic factors in cancer, 2nd edn. UICC TNM Project and Prognostic Factors Committee. Dekker, New YorkGoogle Scholar
  9. 9.
    Tabor E, DiBisceglie AM, Purcell RH (eds) (1991) Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Adv Appl Biotechnol Ser 13:504–514Google Scholar
  10. 10.
    Takayasu K, Furukawa H, Wakao F et al (1995) CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Am J Roentgenol 164:885–890Google Scholar
  11. 11.
    Adson MA (1999) Primary hepatocellular cancers: western experience. In: Blumgart LH (ed) Surgery of the liver and biliary tract. Churchill-Livingstone, New York, pp 1155–1164Google Scholar
  12. 12.
    Pugh RHN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649PubMedCrossRefGoogle Scholar
  13. 13.
    Romani F, Belli LS, Rondinara GF et al (1994) The role of transplantation in small hepatocellular carcinoma complicating cirrhosis of the liver. J Am Coll Surg 178:3779–3784Google Scholar
  14. 14.
    Venook AP, Stagg RJ, Lewis BJ et al (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8:1108–1114PubMedGoogle Scholar
  15. 15.
    Trinchet JC et al from Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261CrossRefGoogle Scholar
  16. 16.
    Castells A, Bruix J, Bru C et al (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injections. Hepatology 18:1121–1126PubMedGoogle Scholar
  17. 17.
    Luporini G, Labianca R, Pancera G (1993) Medical treatment of hepatocellular carcinoma. J Surg Oncol [Suppl]3:115–118CrossRefGoogle Scholar
  18. 18.
    CLIP Group (no authors listed) (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352:17–20CrossRefGoogle Scholar
  19. 19.
    Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–446PubMedCrossRefGoogle Scholar
  20. 20.
    Ortega JA, Krailo MD, Haans JE (1991) Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion of doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J Clin Oncol 9:2167–2176PubMedGoogle Scholar
  21. 21.
    Lai EC, Lo CM, Fan ST Liu CL, Wong J (1998) Postoperative chemotherapy after curative resection of hepatocellular carcinoma randomized trial. Arch Surg 133:183–188PubMedCrossRefGoogle Scholar
  22. 22.
    Lau WY, Leung WT, Ho SKW et al (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801PubMedCrossRefGoogle Scholar
  23. 23.
    Ho S, Lau WY, Leung TWT, Johnson PJ (1998) Internal radiation therapy for patients with primary or metastatic hepatic cancer. A review. Cancer 83:1894–1907PubMedCrossRefGoogle Scholar
  24. 24.
    Lau WY, Ho S, Leung WT, Chan M, Ho R, Johnson PJ, Li AKC (1998) Selective internal radiation therapy for inoperable hepatocellular carcinoma with intraarterial infusion of yttrium90 microspheres. Int J Radiat Oncol Biol Phys 40: 583–592PubMedCrossRefGoogle Scholar
  25. 25.
    Krain L (1972) Gallbladder and extrahepatic bile duct carcinoma: analysis of 1808 cases. Geriatrics 27:1111–1117Google Scholar
  26. 26.
    Altaee MY, Johnson PJ, Farrant JM et al (1991) Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 68:2051–2055PubMedCrossRefGoogle Scholar
  27. 27.
    Schoenthaler R, Philips TL, Castro J et al (1994) Carcinoma of the extrahepatic bile ducts: the University of California at San Francisco experience. Ann Surg 219:267–272PubMedCrossRefGoogle Scholar
  28. 28.
    Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, Benner S (1999) Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17:97–101PubMedCrossRefGoogle Scholar
  29. 29.
    Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186PubMedCrossRefGoogle Scholar
  30. 30.
    Sanz-Altamira PM, O’Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, Saltz LB (2001) A phase II trail of irinotecan (CPT-11) for unresectable biliary tract carcinoma. Ann Oncol 12:501–504PubMedCrossRefGoogle Scholar
  31. 31.
    Matsubara T, Funabiki T, Jinno O, Sakurai Y, Hasegawa S, Imazu H, Ochiai M (1999) p53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepat Pancreat Surg 6:286–293CrossRefGoogle Scholar
  32. 32.
    Fiorentino M, D’Errico A, Altimari A, Barozzi C, Grigioni WF (1999) High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol 8:189–194PubMedCrossRefGoogle Scholar
  33. 33.
    Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D (2000) p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepat Pancreat Surg 7:426–431CrossRefGoogle Scholar
  34. 34.
    Baselga J (2000) Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37[Suppl l]:18–24Google Scholar
  35. 35.
    Boyle P, Hsieh CC, Maisonneuve P et al (1989) Epidemiology of pancreas cancer. Int J Pancreatol 5:327–346PubMedGoogle Scholar
  36. 36.
    Lunch HT, Smyrk T, Kern SE et al (1996) Familial pancreatic cancer: a review. Semin Oncol 23:251–275Google Scholar
  37. 37.
    Durbec JP, Chevillotte C, Bidart JM et al (1983) Diet, alcohol, tobacco, and risk of cancer of the pancreas: a case-control study. Br J Cancer 43:463–470CrossRefGoogle Scholar
  38. 38.
    Norell SE, Ahlbom A, Erwald R et al (1986) Diet and pancreatic cancer: a case-control study. Am J Epidemiol 124: 894–902PubMedGoogle Scholar
  39. 39.
    Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–456PubMedCrossRefGoogle Scholar
  40. 39.
    Ghadirian P, Simard A, Baillargeon J (1991) Tobacco, alcohol, and coffee and cancer of the pancreas. Cancer 67:2664–2670PubMedCrossRefGoogle Scholar
  41. 40.
    American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edn. American Cancer Society, Lippincott-Raven, PhiladelphiaGoogle Scholar
  42. 41.
    NCCN (1997) NCCN practice guidelines for pancreatic cancer. NCCN oncology practice guidelines. Oncology 11: 41–55Google Scholar
  43. 42.
    Yeo CJ, Cameron JL, Lillemoe KD et al (1997) Pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937Google Scholar
  44. 43.
    Moertel CG, Reitemeier RJ (1969) Advanced gastrointestinal cancer — clinical management and chemotherapy. Hoeber, Medical Division, Harper and Row, New York, p 7–42Google Scholar
  45. 44.
    Moertel CG, Childs DS, Reitemeier RJ et al (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867PubMedCrossRefGoogle Scholar
  46. 45.
    Haslam JB, Cavanaugh PJ, Stroup SL (1973) Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341–1345PubMedCrossRefGoogle Scholar
  47. 46.
    Thomas PRM (1996) Radiotherapy for carcinoma of the pancreas. Semin Oncol 23:213–219PubMedGoogle Scholar
  48. 47.
    Gastrointenstional Tumor Study Group (1985) Pancreatic ionther-fract ionated radiation and chemotherapy following curative resection. Arch Surg 120:899–903CrossRefGoogle Scholar
  49. 48.
    Gastrointestinal Tumor Study Group (1987) Effective surgicaladjuvant therapy for pancreatic cancer. Cancer 59: 2006–2110CrossRefGoogle Scholar
  50. 49.
    Sindelar WF, Kinsella TJ (1986) Randomized trial of intraoperative therapy in resected carcinoma of pancreas (abstract). Int J Radiat Oncol Biol Phys 12[Suppl 1]:148CrossRefGoogle Scholar
  51. 50.
    Whittington R, Bryer MP, Haller DG et al (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21:1137–1143PubMedCrossRefGoogle Scholar
  52. 51.
    Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas abd peri-ampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776–784PubMedCrossRefGoogle Scholar
  53. 52.
    Neoptolemos JP, Dunn JA, Moffitt DD et al (2000) ESPAC-1 interim results: European randomized study to assess the roles of adjuvant chemotherapy (5-FU + folinic acid) and adjuvant chemoradiation (40 Gy + 5-FU) in resectable pancreatic cancer (abstract no. 923). Proc Am Soc Clin Oncol 19:238AGoogle Scholar
  54. 53.
    Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937PubMedGoogle Scholar
  55. 54.
    Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843–3850PubMedGoogle Scholar
  56. 55.
    Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, Jinnah R, Evans DB (1997) Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 226:632–641PubMedCrossRefGoogle Scholar
  57. 56.
    Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–323PubMedGoogle Scholar
  58. 57.
    Gastrointestinal Tumor Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000rads) radiation alone, moderate radiation (4000rads) plus 5-fluorouracil and high dose radiation plus 5-fluorouracil. Cancer 58:1705–1710Google Scholar
  59. 58.
    Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of cally unresectable pancreatic carcinoma: Cancer 56:2563–2568CrossRefGoogle Scholar
  60. 59.
    Seydel HG, Stabilem DM, Leichman LP et al (1990) Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group Experience. Cancer 65: 1478–1482PubMedCrossRefGoogle Scholar
  61. 60.
    Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751–755CrossRefGoogle Scholar
  62. 61.
    Treurniet-Donker AD, Van Mierlo MJM, Van Putten WLJ (1990) Localized unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 18:59–62PubMedCrossRefGoogle Scholar
  63. 62.
    Komaki R, Wadler S, Peters T et al (1992) High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. Cancer 69:2807–2812PubMedCrossRefGoogle Scholar
  64. 63.
    Bornman PC, Harris-Jones EP, Tobias R et al (1986) Prospective controlled trial of transhepatic biliary endoprothesis versus bypass surgery for incurable carcinoma of head of pancreas. Lancet 1:69–71PubMedCrossRefGoogle Scholar
  65. 64.
    Schnall SF, Macdonald JS (1996) Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220–228PubMedGoogle Scholar
  66. 65.
    Schultz RM (1995) Future directions for the treatment of human pancreatic carcinoma. Exp Opin Invest Drug 4: 1273–1279CrossRefGoogle Scholar
  67. 66.
    Mallinson CN, Rake MO, Cocking JB et al (1980) Chemotherapy in pancreatic cancer: results of a controlled prospective, and randomised, multicentre trial. Br Med J 281: 1589–1591PubMedCrossRefGoogle Scholar
  68. 67.
    Cullinan S, Moertel CG, Wieand HS et al (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 65:2207–2212PubMedCrossRefGoogle Scholar
  69. 68.
    The Gastrointestinal Tumor Study Group (1986) Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 4:1794–1798Google Scholar
  70. 69.
    Burris HA III, Moore Malcolm J, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  71. 70.
    Tempero M, Plunkett W, Haperen VR, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (1999) Randomised phase II trial of dose intense gemcitabine by standard infusion versus fixed dose rate in metastatic pancreatic adenocarcinoma (abstract no. 1048). Proc Am Soc Clin Oncol 18: 273AGoogle Scholar
  72. 71.
    Butera J, Malachovsky M, Rathore R, Safran H (1998) Novel approaches in development for the treatment of pancreatic cancer. Front Biosci 3:E226–E229PubMedGoogle Scholar
  73. 72.
    Buchler P, Reber HA, Buchler MC, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ (2001) Therapy for pancreatic cancer with a recombinant humanized anti-her2 antibody (Herceptin). J Gastrointest Surg 5:139–146PubMedCrossRefGoogle Scholar
  74. 73.
    Bramhall SR (1997) The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 21:1–12PubMedGoogle Scholar
  75. 74.
    Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8:308–315PubMedCrossRefGoogle Scholar
  76. 75.
    Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O’Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ (2001) Novel allogeneic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19:145–156PubMedGoogle Scholar
  77. 76.
    Van Riel JM, Giaccone G, Pinedo HM (1999) Pancreaticobiliary cancer: the future aspects of medical oncology. Ann Oncol 10[Suppl 4]:296–299PubMedGoogle Scholar
  78. 77.
    Moertel CG (1987) An Odyssey in the land of small tumors. J Clin Oncol 5:1503–1522Google Scholar
  79. 78.
    Larsson C, Shogseid B, Oberg K et al (1988) MEN-1 gene maps to chromosome 11 and is lost in insuloma. Nature 332:85–87PubMedCrossRefGoogle Scholar
  80. 79.
    Wilander E (1989) Diagnostic pathology of gastrointestinal pancreatic neuroendocrine tumors. Acta Oncol 288:363–369CrossRefGoogle Scholar
  81. 80.
    Waltenberger J, Lundin L, Oberg K et al (1993) Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142:71–78PubMedGoogle Scholar
  82. 81.
    Chaudhry A, Gobl A, Eriksson B et al (1994) Different splice variance of CD44 are expressed in gastrinomas but not in other subtypes or endocrine pancreatic tumors. Cancer Res 54:981–986PubMedGoogle Scholar
  83. 82.
    Maton PN (1988) The carcinoid syndrome. JAMA 260: 1602–1605PubMedCrossRefGoogle Scholar
  84. 83.
    Maartensson H, Norbin A, Bengmarks S et al (1984) Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 27:152–158CrossRefGoogle Scholar
  85. 84.
    Kvols LK, Moertel CG, O’Connell MJ et al (1986) Treatment of malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666PubMedCrossRefGoogle Scholar
  86. 85.
    Oberg K, Norheim I, Lind E (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon: longterm results. Cancer Treat Rep 70:1297–1304PubMedGoogle Scholar
  87. 86.
    Legha SS, Valdivieso M, Nelson RS et al (1977) Chemotherapy for metastatic carcinoid tumors: experience with 32 patients and a review of the literature. Cancer Treat Rep 61: 1699–1703PubMedGoogle Scholar
  88. 87.
    Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G (2001) Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60:141–145PubMedCrossRefGoogle Scholar
  89. 88.
    Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ (2001) 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27:404–408PubMedCrossRefGoogle Scholar
  90. 89.
    McCarthy KE, Woltering EA, Anthony LB (2000) In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives (review). Q J Nucl Med 44:88–95PubMedGoogle Scholar
  91. 90.
    Ajani JA, Kegha SS, Karlin DA et al (1983) Combination chemotherapy of metastatic carcinoid tumors with 5-FU, Adriamycin, and Cytoxan (FAX) and 5-FU, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe) (abstract). Proc Am Soc Clin Oncol 2:124Google Scholar
  92. 91.
    Kissinger A, Foley FJ, Lemon JH (1977) Use of DTIC (dacarbazine) in the malignant carcinoid tumors. Cancer Treat Rep 61:101–102Google Scholar
  93. 92a.
    Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232PubMedCrossRefGoogle Scholar
  94. 92b.
    Jensen RT, Gardner JD (1991) Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Dannenberg A, Zakim D (eds) Peptic ulcer and other acid-related diseases. Academic Research Association, New York, pp 117–131Google Scholar
  95. 93.
    Malagelada JR, Edis AJ, Adson MA et al (1983) Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84:1524–1532PubMedGoogle Scholar
  96. 94.
    Norton JA, Doppman JL, Jensen RT (1992) Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215:218Google Scholar
  97. 95.
    Jensen RT, Norton JA (1995) Endocrine tumors of the pancreas. In: Yamada T, Alpers BH, Owyang C et al (eds) Textbook of gastroenterology. Lippincott, Philadelphia, p 2131–2140Google Scholar
  98. 96.
    Doppmann J (1992) Pancreatic endocrine tumors — the search goes on (editorial). N Engl J Med 326:1770–1772CrossRefGoogle Scholar
  99. 97.
    Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome refractory watery diarrhea and hypokalemia. Am J Med 25:375–380CrossRefGoogle Scholar
  100. 98.
    Moertel CG, Hahnley JA, Johnsson LA (1980) Streptozocin alone compared with streptozocin plus fiuorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 303:1189–1193PubMedCrossRefGoogle Scholar
  101. 99.
    Moertel CG, Lefkopoulos M, Lipsitz S et al (1992) Streptozocin, doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 326:519–523PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • S. Mani
  • P. J. Johnson

There are no affiliations available

Personalised recommendations